Literature DB >> 27091791

Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications.

Sven M Francque1, Denise van der Graaff2, Wilhelmus J Kwanten3.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) has become one of the most frequent chronic liver diseases in the Western society and its prevalence is likely to rise even further. An increasing body of evidence shows that NAFLD is not only a potentially progressive liver disease, but also has systemic consequences. More specifically, evidence points out that NAFLD has to be considered as a significant independent risk factor for subclinical and clinical cardiovascular disease (CVD). Long-term follow-up studies demonstrate cardiovascular mortality to be the most important cause of death in NAFLD patients. Moreover, ample evidence associates NAFLD with endothelial dysfunction, increased pulse wave velocity, increased coronary arterial calcifications and increased carotid intima media thickness, all established markers for CVD. Despite of all this evidence, the mechanisms by which NAFLD causally contributes to CVD are not fully elucidated. Furthermore, an extensive overview of all potential pathophysiological mechanisms and the corresponding current data are lacking. In this review we summarise current knowledge, originating from fundamental and clinical research, that mechanistically links NAFLD to CVD. Subsequently, the impact of CVD on current clinical practice and future research in the area of NALFD are discussed.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Clinical implications; NAFLD; Pathophysiology

Mesh:

Year:  2016        PMID: 27091791     DOI: 10.1016/j.jhep.2016.04.005

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  128 in total

1.  "Trans-nonachlor increases extracellular free fatty acid accumulation and de novo lipogenesis to produce hepatic steatosis in McArdle-RH7777 cells".

Authors:  George Eli Howell; Erin McDevitt; Lucie Henein; Charlee Mulligan; Darian Young
Journal:  Toxicol In Vitro       Date:  2018-04-11       Impact factor: 3.500

Review 2.  Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.

Authors:  Jose Ignacio Vargas; Marco Arrese; Vijay H Shah; Juan Pablo Arab
Journal:  Curr Gastroenterol Rep       Date:  2017-09

Review 3.  Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?

Authors:  Margaret Spinosa; Jonathan G Stine
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

Review 4.  NAFLD and liver transplantation: Current burden and expected challenges.

Authors:  Raluca Pais; A Sidney Barritt; Yvon Calmus; Olivier Scatton; Thomas Runge; Pascal Lebray; Thierry Poynard; Vlad Ratziu; Filomena Conti
Journal:  J Hepatol       Date:  2016-07-30       Impact factor: 25.083

5.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

6.  Association between habitual yogurt consumption and newly diagnosed non-alcoholic fatty liver disease.

Authors:  Shunming Zhang; Jingzhu Fu; Qing Zhang; Li Liu; Min Lu; Ge Meng; Zhanxin Yao; Hongmei Wu; Yang Xia; Xue Bao; Yeqing Gu; Shaomei Sun; Xing Wang; Ming Zhou; Qiyu Jia; Kun Song; Yuntang Wu; Huiling Xiang; Kaijun Niu
Journal:  Eur J Clin Nutr       Date:  2019-09-02       Impact factor: 4.016

7.  Cyclin D1 in the Liver: Role of Noncanonical Signaling in Liver Steatosis and Hormone Regulation.

Authors:  Kelley G Núñez; Janet Gonzalez-Rosario; Paul T Thevenot; Ari J Cohen
Journal:  Ochsner J       Date:  2017

8.  Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?

Authors:  Gabriel Tayguara Silveira Guerreiro; Larisse Longo; Mariana Alves Fonseca; Valessa Emanoele Gabriel de Souza; Mário Reis Álvares-da-Silva
Journal:  Hepatol Int       Date:  2021-03-10       Impact factor: 6.047

Review 9.  New perspectives of Lactobacillus plantarum as a probiotic: The gut-heart-brain axis.

Authors:  Yen-Wenn Liu; Min-Tze Liong; Ying-Chieh Tsai
Journal:  J Microbiol       Date:  2018-08-23       Impact factor: 3.422

Review 10.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.